₹427.15
−2.03%NSE close, 16 Nov 2026
−31.94%
Rossari Biotech is a small cap company, listed on NSE under the symbol ROSSARI. At ₹427.15 a share, the market values the whole company at ₹2,366 crore.
In FY26, it reported sales of ₹2,396 crore and a net profit of ₹149 crore, an operating margin of 11.9%. Over the last three years, sales grew 13.1% a year and net profit grew 11.6% a year.
The market values the company at 15.5 times its profit over the last twelve months and 1.68 times its book value; its return on equity is 10.9% and its borrowings are 0.26 times its equity.
Promoters hold 68.14% of the shares. Foreign institutions hold 1.84%, and domestic institutions, mutual funds among them, 14.19%.
Over the past year the share price has fallen 33.3%, and it is 34.5% below its 52-week high.
₹ crore. Consolidated figures.
Intimation of Transcript of Q2 H1 FY 27 for the Earnings Conference Call held on October 19, 2026.
Audio recording of Earnings Conference Call for Q2 & H1 FY 27.
Press Release for Q2 FY 27 Results
| Mar 2026 |
|---|
| Jun 2026 |
|---|
| Sep 2026 |
|---|
| Sales | 464 | 473 | 490 | 498 | 513 | 580 | 544 | 586 | 582 | 685 | 697 | 698 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 400 | 409 | 425 | 432 | 448 | 510 | 476 | 514 | 513 | 608 | 617 | 611 |
| Operating profit | 63.7 | 63.6 | 64.9 | 65.9 | 64.8 | 69.5 | 67.9 | 71.9 | 68.9 | 77.3 | 80.6 | 87.0 |
| Operating margin | 13.7% | 13.5% | 13.3% | 13.2% | 12.6% | 12.0% | 12.5% | 12.3% | 11.8% | 11.3% | 11.6% | 12.5% |
| Other income | 3.5 | 0.4 | 1.0 | 0.7 | 0.6 | 1.8 | 1.2 | 1.6 | 0.5 | 19.1 | 3.2 | 0.6 |
| Interest | 4.3 | 2.5 | 3.7 | 3.7 | 4.9 | 5.5 | 5.7 | 6.1 | 7.7 | 9.1 | 11.0 | 8.7 |
| Depreciation | 15.1 | 16.1 | 15.4 | 15.2 | 18.3 | 18.2 | 17.8 | 18.2 | 19.6 | 23.5 | 25.6 | 30.1 |
| Profit before tax | 47.8 | 45.4 | 46.8 | 47.8 | 42.1 | 47.6 | 45.6 | 49.2 | 42.1 | 63.7 | 47.2 | 48.8 |
| Tax | 13.4 | 11.4 | 12.1 | 12.8 | 10.7 | 13.3 | 12.5 | 12.8 | 9.7 | 18.3 | 12.6 | 10.4 |
| Net profit | 34.4 | 34.1 | 34.9 | 35.3 | 31.7 | 34.4 | 33.6 | 36.9 | 32.8 | 46.0 | 35.1 | 38.9 |
| EPS (₹) | 6.23 | 6.18 | 6.32 | 6.39 | 5.73 | 6.22 | 6.07 | 6.66 | 5.92 | 8.30 | 6.34 | 7.02 |
₹ crore, financial years to March.
| Line | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Sales | 709 | 1,483 | 1,656 | 1,831 | 2,080 | 2,396 |
| Expenses | 586 | 1,300 | 1,433 | 1,582 | 1,815 | 2,110 |
| Operating profit | 123 | 183 | 223 | 249 | 265 | 286 |
| Operating margin | 17.3% | 12.4% | 13.5% | 13.6% | 12.7% | 11.9% |
| Other income | 9.2 | 12.0 | 5.5 | 7.4 | 4.0 | 22.4 |
| Interest | 3.0 | 12.7 | 22.3 | 18.2 | 17.8 | 28.5 |
| Depreciation | 22.8 | 48.1 | 62.9 | 60.4 | 67.1 | 79.1 |
| Profit before tax | 106 | 135 | 143 | 177 | 184 | 201 |
| Tax | 26.8 | 38.6 | 37.0 | 46.9 | 48.8 | 53.3 |
| Net profit | 80.2 | 97.7 | 107 | 131 | 136 | 149 |
| EPS (₹) | 15.56 | 17.81 | 19.46 | 23.68 | 24.66 | 26.95 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 29.4 | 137 | 65.1 | 131 |
| From investing | −299 | −184 | −219 | −49.5 |
| From financing | 292 | 64.9 | 186 | −72.4 |
| Spent on fixed assets | −38.2 | −159 | −265 | −57.4 |
| Free cash flow | −8.9 | −21.1 | −200 | 74.0 |
Margins, returns, debt, tax and cash.
| Line | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Net margin | 11.3% | 6.6% | 6.5% | 7.1% | 6.6% | 6.2% |
| Operating margin | 17.3% | 12.4% | 13.5% | 13.6% | 12.7% | 11.9% |
| Return on equity | – | – | 11.7% | 12.5% | 11.5% | 11.2% |
| Return on capital employed | – | – | 16.7% | 17.0% | 14.7% | 13.2% |
| Return on assets | – | – | 7.8% | 8.3% | 7.2% | 6.5% |
| Debt to equity | – | – | 0.08 | 0.10 | 0.16 | 0.31 |
| Interest coverage | 36.60 | 11.60 | 7.40 | 10.80 | 11.30 | 8.00 |
| Debt to assets | – | – | 0.05 | 0.07 | 0.10 | 0.18 |
| Current ratio | – | – | 2.08 | 1.99 | 1.94 | 1.57 |
| Quick ratio | – | – | 1.54 | 1.32 | 1.28 | 1.05 |
| Cash ratio | – | – | 0.20 | 0.06 | 0.08 | 0.10 |
| Asset turnover | – | – | 1.21 | 1.16 | 1.10 | 1.05 |
| Fixed asset turnover | – | – | 5.28 | 5.82 | 5.88 | 4.28 |
| Inventory turnover | – | – | – | 4.60 | 4.00 | 4.10 |
| Receivables turnover | – | – | 4.70 | 4.30 | 4.40 | 4.30 |
| Gross margin | – | – | – | 29.3% | 31.1% | 30.4% |
| Cash from operations to profit | – | 30.0% | – | – | 101.0% | 44.0% |
| Effective tax rate | 25.2% | 28.6% | 25.8% | 26.4% | 26.5% | 26.6% |
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Outcome of Board Meeting held on October 17, 2026.
Intimation of Earnings Conference Call for investor and analyst on Monday, October 19, 2026 at 04:00 P.M. (IST).
Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.
Intimation of non-participation in the investors and analysts meet scheduled on Monday, August 10, 2026.
Outcome of 17th Annual General Meeting of the Members of the Company along with Proceedings, Voting Results and Scrutinizers Report.
Update on Grant of Options
Press Release dated July 18, 2026 titled " Rossari Biotech announces Q1 FY 27 results
Intimation under Regulation 30 of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015.
Intimation of grant of 4000 options under Rossari Employee Stock Option Plan - 2019.